By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
latest_posts
- 1
Trouvez La Carte De Cr\u00e9dit Id\u00e9ale Pour Vos Besoins En Belgique - 2Instructions to Keep an Inspirational perspective After Cellular breakdown in the lungs Treatment
- 3The most effective method to Pick the Right Material Organization: Your Definitive Aide
- 4McDonald's is bringing two 'KPop Demon Hunters' meals to McDonald's. Here's what they include and when they launch.
- 5I asked ChatGPT who would win a Golden Globes. Here's what it got right — and totally wrong.
- Releasing Learning Experiences: A Survey of the \Learning Made Fun\ Instructive Application
- Step by step instructions to Contrast Lab Jewels and Regular Ones
- Get Cooking: 15 Speedy and Heavenly Recipes for Occupied Individuals
- SpaceX rocket launches 140 satellites into orbit on Transporter-15, aces landing at sea (video)
- In wrangling dark matter, some scientists find inspiration in the Torah, Krishna and Christ
- Track down the Ideal Weight reduction Methodology for Your Way of life
- Cygnus XL brings cargo to the ISS for 1st time | Space photo of the day for Dec. 1, 2025
- 3 back-to-back storms forecast to bring snow and surges of cold air across the Midwest to the Northeast
- Israel explores creation of int'l force with Greece, Cyprus to deter Turkey
